###### Strengths and limitations of this study

-   We will develop and evaluate a method for generating and ratifying clinical standards and indicators of 'appropriate care' for common health conditions which has been designed to overcome deficiencies in current methods.

-   This study will obtain expert consensus on 'appropriate care,' underpinned by evidence, for a range of common medical conditions.

-   The recruitment of healthcare professionals, patients and consumers to review clinical indicators may introduce selection biases.

-   The use of English language clinical practice guidelines may not be representative of all available evidence, and limits the generalisability of study findings.

Introduction {#s1}
============

In Australia, 'appropriate care' (care in line with evidence or consensus-based guidelines) is provided to adults, on average, only 57% of the time, with large variations across common medical conditions and providers.[@R1] Problems with clinical practice guidelines (CPGs), standards and indicators (see [box 1](#B1){ref-type="boxed-text"} for definitions) are commonly cited as one of the barriers to providing appropriate care[@R2]; these include large numbers of repositories and guidelines; duplication and overlap among guidelines; differing recommendations for care practices; lack of currency; inconsistent structure and content; voluminous documents which are not easy to assimilate or use[@R3]; and recommendations which are often vague and difficult to measure.[@R2] In addition, most CPGs lack detail of how evidence was interpreted and weighted to formulate recommendations, offer little opportunity for end-users to provide formal feedback[@R8] and have been developed by people with (often undisclosed) professional or commercial conflicts of interest (COIs).[@R2] Box 1Definitions for clinical practice guideline, standard, indicator and tool.A clinical practice guideline:'Statements that include recommendations intended to optimize patient care that are informed by a systematic review of evidence and an assessment of the benefits and harms of alternative care options.[@R10]A clinical standard[@R2]:is an agreed process that should be undertaken or an outcome that should be achieved for a particular circumstance, symptom, sign or diagnosis (or a defined combination of these)should be evidence based, specific, feasible to apply, easy and unambiguous to measure, and produce a clinical benefit and/or improve the safety and/or quality of care, at least at the population level.If a standard cannot or should not be complied with, the reason/s should be briefly stated. A clinical indicator[@R2]:describes a measurable component of the standard, with explicit criteria for inclusion, exclusion, time frame and setting.A clinical tool[@R2]:should implicitly or explicitly incorporate a standard or a component of a standardshould constitute a guide to care that facilitates compliance with the standardshould be easy to audit, preferably electronically, to provide feedbackshould be able to be incorporated into workflows and medical records.

Implementability of CPGs is a key factor affecting their perceived utility and uptake[@R11]; in response, international efforts are being directed at developing clinical standards and indicators to identify evidence and service delivery gaps and areas for improvement, and understand and measure the quality of care provided.[@R16] Emerging schools of thought suggest that 'appropriate care' may be enhanced through greater patient (health consumer) engagement.[@R12] This could be facilitated by involving patients and interested laypeople as well as healthcare professionals (HCPs) in CPG development,[@R6] and using online technologies to enhance transparency, accessibility and currency of both content and development processes.[@R6]

The strategies employed in this protocol aim to mitigate problems with existing CPG development processes ([table 1](#T1){ref-type="table"}) by adopting a single approach to avoid duplication, using an ongoing and iterative documentation process to facilitate transparent synthesis of up-to-date information and make its provenance accessible, and requiring all participants to declare their COIs.[@R2] Indicators will be developed using selection criteria to reflect 'essential' clinical practice and be expressed one concept at a time in plain English to help create standards that are clear, concise, measurable and easy to use.

###### 

Key aspects of the *STANDING Collaboration* methodology, designed to mitigate issues with current CPG development

  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  CPG development issue                                                                                    *STANDING Collaboration* methodology and rationale
  -------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Large numbers of repositories and guidelines[@R2]                                                        Single approach negates the need for, and replaces aggregated findings from, a large number of repositories and guidelines

  Duplication and overlap[@R2]                                                                             

  Different recommendations for care practices[@R2]                                                        Methodology will produce a single set of nationally agreed evidence-based clinical indicators, representative of 'appropriate care' for a range of common medical conditions, reflecting consensus recommendations for care practices

  Lack of currency[@R2]                                                                                    Methodological vehicle (interactive, live and online wiki-based platform) will facilitate ongoing review and ease of updating

  Inconsistent structure and content[@R2]                                                                  Uniform methodological approach and format will ensure consistent structure and content

  Hard-to-use voluminous documents[@R2]                                                                    Methodological vehicle (live and online wiki-based platform) and consistent organisation of indicators according to phases of care will facilitate ease of access and use

  Hard-to-measure recommendations[@R2]                                                                     Uniform methodological approach will ensure consistent structure and content for indicators, which will be formatted to ensure 'measurable components of the standard, with explicit criteria for inclusion, exclusion, time frame and setting'[@R2]

  Management of conflicts of interest[@R2]                                                                 Research methodology requires participants to declare any conflicts of interest, and has a defined management strategy for these\
                                                                                                           The source and provenance of each standard, indicator and suggestion will be logged and can be viewed

  Inclusive, catering for all target audiences[@R19] [@R23]                                                This method allows for all healthcare professional types and patients\
                                                                                                           or consumers to register and review indicators

  Lacking details on how evidence was sourced, interpreted and managed to formulate recommendations[@R8]   All reviewers' comments and recommendations will be logged, classified and presented in subsequent rounds according to whether and why they have been incorporated into the next iteration\
                                                                                                           This allows tracking of the evolution of the standards and indicators from the original recommendations on which they were based to their final iteration, as well as the nature and influence of review feedback in shaping the standard
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

CPG, clinical practice guideline.

The aims of the *STANDING Collaboration* study are to (1) provide proof of concept for an alternative method for creating sets of nationally-agreed evidence-based standards and clinical indicators, and (2) obtain consensus on 'appropriate care' for a range of common medical conditions. To do so, we will use a three-phase approach to engage relevant stakeholders, develop clinical indicators representative of 'appropriate care' (which constitute the standard) for a range of common conditions, and evaluate our processes, products and feasibility. We plan to develop an inclusive, transparent, collaborative process, which allows HCPs and patients or consumers to develop and keep up-to-date clinical standards comprising indicators with defined attributes, using an online curated wiki-based platform to facilitate ongoing review and updating of the standard, or individual indicators, as soon as new evidence emerges. In this study, the term 'wiki' refers to an interactive information management system which will allow users (eg, HCPs and patients) to collaborate directly in formulating and refining indicators that are relevant to their clinical practice and lived experience.[@R21] The source and provenance of each indicator, including all suggestions, will be posted online and updated as necessary.

Methods and analysis {#s2}
====================

Our three-phase approach ([figure 1](#F1){ref-type="fig"}) comprises:

![Overview of *STANDING Collaboration* research methodology and definitions for participant groups. CPG, clinical practice guideline.](bmjopen-2016-014048f01){#F1}

1.  stakeholder analysis;

2.  development and test of a process for creating clinical indicators representative of 'appropriate care' for a range of common conditions;

3.  evaluation of processes, products and feasibility.

Phase 1 {#s3}
=======

In order to gain an understanding of potential barriers, facilitators and the overall feasibility of the *STANDING Collaboration* methodology, stakeholder perspectives will be captured through a series of semistructured qualitative telephone interviews. HCPs and consumers will be invited to participate. Relevant medical colleges, professional and consumer associations and networks will be contacted, using publicly available information, to request assistance with the recruitment of interview participants. Invitations will comprise email notifications to members and media releases and articles within newsletters, asking potential participants to contact the Research Team members. The telephone interviews will be conducted at a time convenient to the research team member and the participant. Based on the sample sizes reported in similar stakeholder analyses,[@R23] we anticipate conducting approximately 18--25 interviews in total (9--13 interview participants per stakeholder type), or until saturation is reached.

Using guidelines for stakeholder analyses[@R25] and the schedules from previous qualitative research as a guide,[@R19] a range of topics will be explored in the interviews ([table 2](#T2){ref-type="table"}).

###### 

Topics (and their rationale) for exploration in the qualitative stakeholder interviews

  Interview topic                                                                                                                       Rationale
  ------------------------------------------------------------------------------------------------------------------------------------- -------------------------------------------------------------------------------------------------------------------------------------------------
  Strength and limitations of current CPGs, clinical standards and indicators (eg, in terms of development, availability and utility)   Background information regarding participants' understanding of the development, availability and utility of CPGs
  Barriers, facilitators and the overall feasibility of the *STANDING Collaboration* methodology                                        To refine the *STANDING Collaboration* methodology according to stakeholders' needs
  Possible integration of standards into patient decision support technologies and what these would comprise                            To tailor the content and format of clinical standards and indicators to optimise fitness for purpose
  Priorities for standard development topics (ie, medical conditions)                                                                   To determine methods and data sources for selecting priority medical conditions for indicator development in the *STANDING Collaboration* study

CPG, clinical practice guideline.

Interviews will be recorded with consent and transcribed by a professional transcription company. Transcripts and summaries will be returned to participants for the purpose of making comments or corrections and providing feedback on the findings.[@R26] Content analyses will be used to derive common themes. We will use open coding and inductive reasoning with two coders to group similar responses into categories and assign labels capturing specific themes. Any discrepancies will be discussed among Research Team members. After agreement is reached on the composition and label for each category, we will assign (axial coding) categories to the central phenomena of interest ([table 2](#T2){ref-type="table"}).[@R27]

Phase 2 {#s4}
=======

Clinical indicators will be developed for individual conditions using a four-stage process:source, select and search relevant CPGs;extract all concepts from each CPG together with the relevant text in which they appear (original recommendation), and tabulate common concepts to select, draft and format the proposed clinical indicators based on identified concepts;review the indicators internally;review the indicators externally.

Stage I: source, select and search relevant CPGs {#s4a}
------------------------------------------------

Interview data from the stakeholder analysis (phase 1) will be used in conjunction with national health priority areas, burden of disease and prevalence data to identify candidate conditions for clinical standard and indicator development.[@R1] Clinical indicators will be drawn initially from the latest CPGs. A systematic search will be undertaken of national-level Australian CPGs endorsed by the National Health and Medical Research Council, and international-level guidelines from the National Institute for Health and Care Excellence in England, Scottish Intercollegiate Guidelines Network, and the Agency for Healthcare Research and Quality's National Guideline Clearinghouse in the USA, and the Guidelines International Network. In the absence of Australian national or international CPGs, relevant professional medical college and association CPGs may also be searched, as well as those published at state or professional level and in international journals. Details of the search strategy are provided in appendix A, online [supplementary file 1](#SP1){ref-type="supplementary-material"}.[@R29] In order to describe the quality of the evidence sources from which our clinical indicators will be derived, two members of the Research Team will independently appraise CPGs using the AGREE-II (Appraisal of Guidelines for Research and Evaluation II) tool.[@R31]
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Stage II: select, draft and format proposed indicators {#s4b}
------------------------------------------------------

Recommendations (and their key underlying concepts) from each CPG will be collated and used to inform the content of the proposed clinical indicators. Not all recommendations published in CPGs will become indicators. Recommendations will be flagged for potential exclusion based on the following criteria:strength of the wording of the recommendation (ie, 'may\' and 'could\' statements would be excluded; 'should\' and 'must\' statements would be included)vague guiding or aspirational statements and those without recommended actionsconflicting recommendations from less recent CPGs and those with lower AGREE-II scores.

All clinical indicators will be written in plain English, one concept at a time, using a structured and standardised format (eg, commencing with the inclusion criteria followed by the compliance action)[@R7] ([table 3](#T3){ref-type="table"}). For each condition, indicators will be arranged according to phases of care (ie, screening, diagnosis, assessment, acute care, ongoing care) so that together, they constitute a clinical standard amendable to inclusion as a clinical tool over the patient journey.

###### 

Examples of clinical indicators from *CareTrack Australia* [@R1] that were written in plain English, one concept at a time using a structured and standardised format

  Condition                                                                                                                                                                            Original recommendation (source)                                                                                                                                                                                                                                                                                                                                                                                                                      Level of evidence                Indicator
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------ ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- -------------------------------- --------------------------------------------------------------------------------------------------------------------------------------------
  Asthma                                                                                                                                                                               Treatment with a preventer medication is recommended for patients who have asthma symptoms more than three times per week or use a SABA more than three times per week[@R50]                                                                                                                                                                                                                                                                          I                                Patients who reported asthma symptoms more than three times per week were prescribed preventer medication (Seretide, Symbicort, Flixotide)
  Patients with asthma who report using SABA more than three times per week were prescribed preventer medication                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              
  Hypertension                                                                                                                                                                         Initiate antihypertensive drug treatment immediately in patients with hypertension with any of the following:grade 3 hypertension or isolated systolic hypertension with widened pulse pressure (SBP ≥160 mm Hg and DBP ≤70 mm Hg)associated conditions or evidence of end-organ damage (regardless of BP)high absolute risk of cardiovascular disease, based on the presence of markers of high risk or as estimated using a risk calculator[@R51]   Consensus-based recommendation   Patients with hypertension and isolated SBP ≥160 and DBP \<70 or with widening pulse pressure are prescribed antihypertensive therapy
  Patients with hypertension and end-organ failure are prescribed antihypertensive therapy                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    
  Patients with hypertension and at high risk (diabetes, previous stroke/CVA or chronic kidney disease) of developing coronary heart disease are prescribed antihypertensive therapy                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          

BP, blood pressure; CPG, clinical practice guideline; CVA, cerebrovascular accident; DBP, diastolic blood pressure; SABA, short-acting beta2-agonist; SBP, systolic blood pressure.

Stages III and IV: iterative review using a modified e-Delphi approach {#s4c}
----------------------------------------------------------------------

Stages III and IV will involve online wiki-based reviews of proposed clinical indicators; initially by way of an internal review between the Research Team and Curator Group (stage III), followed by an external review by the Curator Group and HCPs and consumers who choose to register to the site (Wiki Registrants) and provide feedback on the proposed clinical indicators.[@R7] This approach has been chosen to facilitate the number and spread of individuals' perspectives obtained and avoid domination of the consensus process by one or a few participants, and to optimise face validity of the final set of clinical standards and indicators.[@R7] All *STANDING Collaboration* participants (Research Team, Clinical Champion, Curator Group members, and Wiki Registrants) will be required to complete a COI declaration, which will be taken into consideration when accepting or rejecting suggestions, and logged with the provenance of each indicator for transparency.[@R9]

Stage III: internal review processes {#s4d}
------------------------------------

Internal reviews will first be conducted within our Research Team, and subsequently by our Clinical Champion and Curator Group members who will comprise a mix of at least two members of the following: clinicians (eg, general practitioners, medical specialists, allied health professionals, nurses), researchers, policymakers or public health specialists or healthcare quality improvement experts, and consumers. Depending on their self-reported scope of practice, expertise and interest, Curator Group members (including consumers) may be able to participate in review panels for more than one condition. The total number of invitations to potential Curator Group members will depend on the skill mix of those invited and the overall pattern of recruitment. This selection strategy is supported within the Delphi process literature with studies using similar criteria to choose potential participants (eg, renown, member of an organisation, recommendation, years of experience, willingness to participate, availability, interest).[@R7]

The internal review will consist of a maximum of three rounds to allow sufficient testing of the subsequent phase of the process (ie, external review). In the first round, drafts of proposed clinical indicators, and the recommendations on which they are based, will be sent via email to the Curator Group members. The review criteria to be used are based on the methods from previous studies for developing and measuring indicators of appropriate care.[@R1] Curator Group members will be asked to: recommend indicators for inclusion (with or without amendments) or exclusion, provide comments in relation to three key criteria: evidence, feasibility and importance (appendix B, online [supplementary file 2](#SP2){ref-type="supplementary-material"}) and make additional suggestions (with supporting material). In addition, Research Team members will pose specific questions to the Curator Group members about individual indicators to highlight inconclusive or conflicting CPG recommendations, or to clarify definitions for inclusion criteria and compliance actions. In particular, consumer members of the Curator Group will be asked to vet the plain English wording of clinical indicators and a linked glossary of terms to ensure that content is appropriately targeted to the consumer audience. In this round, Curator Group members will complete their assignments independently to minimise 'group-think.'[@R40] Research Team members (WBR, PDH, LKW, JHS) will collate the feedback and revise the content, structure and format of each indicator. The refined set of indicators (including the original indicators and any feedback and suggestions) will be sent to the same Curator Group members for a second round of scoring. The same approach will be used in the second round, with a request for further refinement and identification of indicators to be included or excluded. If necessary, Curator Group members will discuss the proposed set of indicators via a third round teleconference, with a view to achieving consensus and approving the indicators for the external online wiki-based review process.

10.1136/bmjopen-2016-014048.supp2

Stage IV: external review processes {#s4e}
-----------------------------------

External reviews will be conducted by HCPs and consumers who have registered to this wiki as reviewers (Wiki Registrants). Relevant medical colleges, professional and consumer associations and networks will be contacted to request assistance with the identification of potential clinical indicator reviewers. Invitations will be by email, media releases and articles within newsletters. HCPs and consumers will self-nominate as reviewers for one or more of the *STANDING Collaboration* conditions based on their interests, scope of practice and experience.[@R35] Wiki Registrants for this process will be required to declare their COIs, which will be taken into account by the Clinical Champion and Curator Group when considering reviewers' feedback on the indicators.[@R9]

The external review will involve an interactive wiki-based process where indicators for each condition from round 3 of the internal review will be posted on an online wiki site. A software development company will be engaged to purpose design and custom build the wiki for this project. The wiki 'live' time for each version will depend on the recruitment rate of reviewers and the progress of their reviews, but is anticipated to be no longer than 3 months per round. Reviewers will provide comments on indicators in relation to the three key criteria: evidence, feasibility and importance (appendix B, online [supplementary file 2](#SP2){ref-type="supplementary-material"}), make recommendations (ie, inclusion, inclusion with amendments, exclusion, hold) and be able to suggest edits in real time. The Clinical Champion and Curator Group for each condition will follow-up and manage external reviewers' responses, and make final recommendations for that version regarding the inclusion, content, structure and format of indicators. The Clinical Champion and Curator Group will use supporting references when considering and responding to each suggestion related to whether and why they have been included or rejected. In addition, all external reviewers' comments and recommendations will be logged, classified and presented in subsequent rounds according to whether and why they have or have not been incorporated into the next iteration. This will allow tracking of the evolution of the standards and indicators from the original recommendations on which they were based to their final iteration, as well as the nature and influence of review feedback in shaping the standard. Once the indicators are 'stable' with no further significant changes being suggested, that version of the standard will be published as comprising a set of clinical indicators that represents 'appropriate care\' for Australians with the candidate conditions at that time. Endorsement will then be sought by relevant professional bodies and consumer organisations. For each medical condition that has undergone indicator development via the *STANDING Collaboration* process, it will be possible for evidence to be monitored by the Curator Group (or a subgroup comprised of key members of the Curator Group) in order to update standards and indicators as necessary. For each condition, our initial monitoring plan involves using information from automated database searches and feedback from the wiki to initially update indicators every three months and, once stable, at a minimum of every six months.

Phase 3 {#s5}
=======

A multimethods evaluation of the process and products of phases 1 and 2 of our research methodology will be undertaken ([table 4](#T4){ref-type="table"}). Three data sources will be used to inform the evaluation: (A) engagement and utilisation statistics sourced from the wiki logs---these will include demographics of users and rates, times and nature of use; (B) the nature and content of Wiki Registrant, Curator Group and Clinical Champion comments (eg, the format and rationale of proposed changes to indicators, level of agreement between reviewers and resulting changes to the indicators); and (C) all users and stakeholders' perspectives on the process, usability and appropriateness of the vehicle for developing the standards (ie, the wiki) as well as the acceptance and utility of the final sets of standards and indicators themselves.

###### 

Description of the phase 3 evaluation of phase 1 and phase 2

  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Phase 3: Evaluation of processes, products and feasibility   Phase 1: Stakeholder analyses                                         Phase 2: Development of clinical indicators representative of 'appropriate care' for a range of common conditions
  ------------------------------------------------------------ --------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Aim and purpose of evaluation                                Participants' perceptions and experiences of the engagement process   Participants' engagement with, and utilisation of, clinical indicator development process\
                                                                                                                                     Participants' perspectives on the process, usability and appropriateness of the clinical indicator development approach used, and the final sets of standards and indicators

  Participants                                                 Phase 1: stakeholders                                                 Phase 2: internal reviewers\
                                                                                                                                     (Research Team, Clinical Champions, Curator Group members)\
                                                                                                                                     Phase 2: external reviewers\
                                                                                                                                     (Wiki Registrants)

  Methods                                                      Qualitative interviews                                                Database (wiki) usage and content analyses\
                                                                                                                                     Qualitative focus groups (internal reviewers)\
                                                                                                                                     Online survey (external reviewers)

  Data sources                                                 Interview data                                                        Wiki logs\
                                                                                                                                     Interview and survey data

  Analysis                                                     Content analysis\                                                     Descriptive statistics (wiki logs, online survey) and content analyses (wiki, interview and survey data)
                                                               Inductive reasoning                                                   
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Participants will be invited to provide feedback regarding their experiences and perspectives via one of three data collection methods: (1) online user perspectives survey (for external reviewers); (2) semistructured interviews (for Review Panel members and the Clinical Champion); and (3) interviews and focus groups (for phase 1 stakeholders, following publication of the sets of indicators) ([table 4](#T4){ref-type="table"}). Both quantitative and qualitative analyses of these three data sources will be undertaken including: descriptive statistics for the characteristics of wiki users, their engagement and patterns of use, frequency counts and content analyses of ratings and free-text responses from the online user perspectives survey, semistructured interviews and focus groups ([table 4](#T4){ref-type="table"}). Using these data, recommendations will be developed regarding the overall feasibility of the wiki process for future indicator development. The next phase of the research is to study the implementation of the standards as a translational tool for clinical practice and ongoing audit.

Ethics and dissemination {#s6}
========================

Ethical approval {#s6a}
----------------

Human Research Ethics Committee approval has been granted from the University of South Australia (protocol number 0000035183). All *STANDING Collaboration* participants and reviewers will be required to give informed consent (for their chosen study phase(s)) and complete a COI declaration prior to participation, which will be recorded and managed according to an established protocol (appendix c, online [supplementary file 3](#SP3){ref-type="supplementary-material"}).[@R43]
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Dissemination {#s6b}
-------------

We will submit the results of the study to relevant national and international journals with the intention of publishing the results widely. As well, we will make national and international presentations to stakeholder groups including those involving patients, researchers, clinicians, managers and policymakers.

Discussion {#s7}
==========

Notwithstanding the large number of CPGs currently available, delivery of 'appropriate' healthcare in Australia and internationally is highly variable and leaves considerable room for improvement. A number of major difficulties have been identified with current CPGs and their development. Our alternative approach for keeping evidence accessible and up to date has been designed to mitigate problems with existing processes. Here, we describe a protocol for developing and testing a process for creating clinical standards, embodied in clinical indicators.

This process has been designed to systematically address many of the problems identified with current CPGs and their development. The approach is characterised by being inclusive (HCPs, researchers and consumers), transparent (all reviewers' suggestions are logged, with their provenance, as accepted or rejected by the Clinical Champion and Curator Group), up to date (revisions will be ongoing after a version is published), easy to use (one concept per indicator), written in plain English and able to be integrated into the sequence of work flow in managing a condition.[@R2]

Findings from this study will be used to inform the design of future studies using Delphi processes to establish consensus on recommended healthcare, and will be relevant for national and international researchers, policymakers, healthcare practitioners and patients. Specifically, there is potential for standards and indicators developed using this methodology to be assembled to comprise the content of electronic tools for the basic care of common conditions (ie, reflects 'essential' Australian clinical practice; appendix B, online [supplementary file 2](#SP2){ref-type="supplementary-material"}). It is envisaged that the clinical tool ([box 1](#B1){ref-type="boxed-text"}) will[@R2]:implicitly or explicitly enunciate the clinical standard for the basic care of the condition in questioninform HCPs, patients and carers about that conditionguide caredocument what care has been offered and what has not (and why)be amenable to audit (preferably automated) so that feedback can be provided---at clinical indicator, patient, provider, facility and eventually population levels.

We recognise several limitations to our study. The inclusion of only English language CPGs, for pragmatic purposes and contextual consistency, may not be representative of all available evidence and limits the generalisability of our findings. Reviewers will be invited to participate and self-nominate for conditions that are within their scope of practice, interest or experience (ie, healthcare providers and consumers) which introduces a selection bias. Clinical indicators will be developed from recommendations in existing CPGs, which means there is potential for problems with current CPG development processes to contaminate our final sets of indicators and standards. The aim of this study is to provide proof of concept and test a new methodology. Our intention is that the key approaches and characteristics of the *STANDING Collaboration* clinical standard and indicator development process (ie, governance structure, transparency, HCP and consumer engagement and codesign, access to provenance of both accepted and rejected suggestions, and use of online technologies to facilitate keeping the indicators up to date) will be universally applicable, and be able to be tailored to other healthcare settings and structures.[@R30] We aim to ameliorate these limitations by adopting a collaborative user-centred approach where feedback from both consumer and HCP groups is sought, communicated transparently and incorporated into guidance for others who wish to develop clinical standards and indicators.[@R6]
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